Navigation Links
Further Evidence that the PhotoActivation of PRP (PAPRP) is a Novel and Effective Treatment for Osteoarthritis and Knee Pain
Date:7/21/2013

Melbourne, Australia (PRWEB) July 22, 2013

A 40 Patient Clinical Trial using AdiStem PRP PhotoActivation is being planned in Australia following two initial case studies published in the “British Medical Journal”. One was on a 50 year old woman in Melbourne with left knee osteoarthritis and the other on a 38 year old man with traumatic chondral lesion of the left knee.

The 50 year old woman had progressive and symptomatic left knee osteoarthritis and recently received treatment where her knee was injected with PhotoActivated Platelet Rich Plasma (PAPRP). Following treatment her Numerical Pain Rating Scale (NPRS) improved at Week 1 suggesting an immediate anti-inflammatory and analgesic benefit of PAPRP. At 18 weeks following the initial PAPRP injection, the patient reported a perceived improvement of 80% in both pain and function as measured by NPRS and WOMAC. No complications were noted.

The use of PRP has been expanding rapidly. Platelets contain an abundance of growth factors, cytokines and bioactive molecules crucial to hard and soft tissue healing and leading to a significant reduction in pain. It is now recognized that the additional use of low intensity light at specific frequencies increases both the release of anti-inflammatory agents and beta endorphins -- the bodies natural pain reliever -- which contributes to the patient’s comfort.

During the procedure, the patients’ autologous blood is centrifuged for 10 minutes. This yields plasma which is then withdrawn into a sterile tube and exposed to photoactivation for 10 minutes using the AdiLight-2 device from AdiStem Ltd, Hong Kong. The resulting PAPRP is then injected into the knee. The process should be repeated 3 times – 1 week apart. (BMJ Case Reports Published online 26 March 2013; doi: 10.1136/bcr-2012-007463)

An earlier study by the same doctor (Dr. Julien Freitag), which was also published in the “British Medical Journal”, used PAPRP on a healthy 38 year old man with traumatic chondral lesion of the left knee following a basketball injury. The patient experienced functional improvement within 2 weeks of commencing treatment and a perceived 100% improvement at Week 15. No complications were noted. (BMJ Case Reports Published Online: 17 December 2012; doi: 10.1136/bcr-2012-006858)

The forthcoming 40 patient clinical trial using PAPRP is now being undertaken by Dr. Julien Freitag on patients with knee osteoarthritis and knee joint pain. These conditions are normally difficult to treat - and major causes of disability and chronic pain amongst millions of people.

More information from http://www.adistem.com.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10940829.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Going a step Further: Phase IV and Post-Marketing Observational Studies add Value to new Therapies, life Science Webinar Hosted by Xtalks
2. Prova Education Hires Oncology Expert Alana Brody to Further Expand its Oncology Education and Opportunities
3. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
4. Medifirst Solutions, Inc. Announces Further Update To Shareholders
5. Probiotic Action Announces Further Exploration of Probiotics for Acne with New Information from the LA Times
6. Dr. Carlos Szajnert, Announced today his Commitment to Further Educate his Patients on the Benefits of Cord Blood Stem Cells
7. UCLA researchers further refine NanoVelcro device to grab single cancer cells from blood
8. Molecular Detection Inc. Further Strengthens Patent Portfolio Broadly Covering Detection of Antibiotic-Resistant Bacteria
9. China Cord Blood Corporation to Further Consolidate its Corporate Structure
10. OxThera Raises Capital for Further Clinical Development of Oxabact(R)
11. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):